Business Standard

PE firm Multiples picks up 9.3% stake in BDR Pharma for Rs 685 cr

Multiples is the first private equity (PE) investor in BDR Pharma

rupee
Premium

The funds will be used by the company to build additional research and development (R&D) capabilities in current and emerging areas, invest in manufacturing capacity expansion and enhance the degree of vertical integration

Sohini Das Mumbai
Private equity firm Multiples has picked up a 9.3 per cent stake in BDR Pharmaceuticals International for Rs 685 crore. The funds will be used by the company to build additional research and development (R&D) capabilities in current and emerging areas, invest in manufacturing capacity expansion and enhance the degree of vertical integration. BDR also plans to pursue inorganic expansion using the funds raised.

Multiples is the first private equity (PE) investor in BDR Pharma. "The consortium of investors participating along with Multiples include institutional investors such as the investment arm of Times Group, QRG Invest (Havells Family Office), and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in